Published in J Acquir Immune Defic Syndr on August 01, 2006
Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet (2011) 1.92
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis (2008) 1.81
Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition. PLoS One (2008) 1.11
Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. J Infect Dis (2010) 1.03
Hearing loss in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents. Pediatr Infect Dis J (2012) 0.99
Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol (2011) 0.97
Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status. AIDS Res Hum Retroviruses (2008) 0.95
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother (2007) 0.95
HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis (2012) 0.92
Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-γ inhibition. Clin Pharmacol Ther (2014) 0.89
Hearing loss among HIV-seropositive and HIV-seronegative men and women. JAMA Otolaryngol Head Neck Surg (2015) 0.83
Evaluation of Hepatic Mitochondria and Hematological Parameters in Zidovudine-Treated B6C3F(1) Mice. AIDS Res Treat (2012) 0.80
Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab (2008) 0.79
Comparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell counts. AIDS (2014) 0.76
The Silent Epidemic - Frailty and Aging with HIV. Total Patient Care HIV HCV (2016) 0.75
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A (2004) 2.15
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 2.04
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA (2008) 1.88
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity (2008) 1.76
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis (2008) 1.60
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS (2005) 1.55
Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 1.54
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology (2009) 1.54
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
4: Acute community-acquired meningitis and encephalitis. Med J Aust (2002) 1.52
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
The widening gap between clinical, teaching and research work. Med J Aust (2009) 1.46
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology (2009) 1.44
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Academic health science centres in Australia: let's get competitive. Med J Aust (2011) 1.43
Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS (2007) 1.43
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol (2003) 1.39
Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology (2005) 1.39
Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes (2007) 1.35
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes (2005) 1.29
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
HIV-associated opportunistic infections of the CNS. Lancet Neurol (2012) 1.22
Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis (2006) 1.22
Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain (2007) 1.21
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis (2005) 1.21
Sleep, function and HIV: a multi-method assessment. AIDS Behav (2013) 1.20
Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol (2006) 1.19
Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol (2010) 1.17
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol (2010) 1.15
Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol (2007) 1.15
Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther (2003) 1.14
Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir Ther (2005) 1.14
Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis (2010) 1.13
Saving the clinician-scientist: report of the ANA long range planning committee. Ann Neurol (2006) 1.12
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol (2002) 1.11
Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol (2003) 1.11
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol (2009) 1.09
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr (2002) 1.09
Pharmacogenetics of drug hypersensitivity. Pharmacogenomics (2010) 1.09
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
The medicinal chemistry of dengue fever. J Med Chem (2009) 1.08
Epidermal reinnervation after intracutaneous axotomy in man. J Comp Neurol (2003) 1.08
Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS (2005) 1.08
Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol (2005) 1.08
Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol (2011) 1.07
Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology (2005) 1.07
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06
Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis (2006) 1.06
Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. Brain (2011) 1.05